Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nimotuzumab with Chemoradiation for Rectal Cancer
NCT01899118Phase 2Unknown
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Apr 2013
- Primary completion
- Apr 2016
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nimotuzumab in rectal cancer, sponsored by Zhejiang Cancer Hospital. Primary endpoint: Pathology complete remission rate at 1 year. Status: unknown.
02
Drugs
nimotuzumab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT01899118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01899118.